3-(bis(2-methoxyethyl)amino)-6-bromo-N²,N²,N⁵,N⁵-tetrakis(2-methoxyethyl)pyrazine-2,5-dicarboxamide | 960510-33-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3-(bis(2-methoxyethyl)amino)-6-bromo-N²,N²,N⁵,N⁵-tetrakis(2-methoxyethyl)pyrazine-2,5-dicarboxamide
• 英文别名: 3-[bis(2-methoxyethyl)amino]-6-bromo-2-N,2-N,5-N,5-N-tetrakis(2-methoxyethyl)pyrazine-2,5-dicarboxamide
• CAS: 960510-33-2
• 化学式: C₂₄H₄₂BrN₅O₈
• 分子量: 608.53
• InChiKey: OCWXZTYSYIQPSV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  38
• 可旋转键数：
  21
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  125
• 氢给体数：
  0
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  3-(bis(2-methoxyethyl)amino)-6-bromo-N²,N²,N⁵,N⁵-tetrakis(2-methoxyethyl)pyrazine-2,5-dicarboxamide 、 三氟乙酸 在 四(三苯基膦)钯 作用下， 以 乙腈 为溶剂， 反应 2.0h， 以10%的产率得到3,6-bis(bis(2-methoxyethyl)amino)-N²,N²,N⁵,N⁵-tetrakis(2-methoxyethyl)pyrazine-2,5-dicarboxamide bis(trifluoroacetate)
  参考文献：
  名称：

  WO2007/149479

  摘要：

  公开号：
• 作为产物：
  描述：

  双(2-甲氧基乙基)胺 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.5h， 以26%的产率得到3-(bis(2-methoxyethyl)amino)-6-bromo-N²,N²,N⁵,N⁵-tetrakis(2-methoxyethyl)pyrazine-2,5-dicarboxamide
  参考文献：
  名称：

  WO2007/149478

  摘要：

  公开号：

文献信息

• [EN] COMPOSITIONS AND METHODS FOR ASSESSING EYE VASCULATURE<br/>[FR] COMPOSITIONS ET MÉTHODES POUR ÉVALUER LE SYSTÈME VASCULAIRE DE L'ŒIL
  申请人：MEDIBEACON INC

  公开号：WO2016183351A1

  公开（公告）日：2016-11-17

  The present disclosure relates to compositions and methods for assessing blood vessels and organs of the body, more specifically to methods for assessing the vasculature of the eye.

  本公开涉及用于评估人体血管和器官的组合物和方法，更具体地说是用于评估眼部血管的方法。
• METHODS FOR RENAL FUNCTION DETERMINATION
  申请人：MediBeacon Inc.

  公开号：US20190125902A1

  公开（公告）日：2019-05-02

  The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The method includes administering a pyrazine compound of Formula I to a patient and monitoring the rate in which the kidneys of the patient eliminate the pyrazine from the systemic circulation of the patient. The pyrazine compound fluoresces when exposed to electromagnetic radiation which is detected using one or more sensors. The rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.

  本公开涉及用于确定肾小球滤过率或评估患者肾功能的系统和方法。该方法包括向患者施用化合物I的吡嗪类化合物，并监测患者的肾脏从患者的全身循环中排除吡嗪的速率。当暴露于电磁辐射时，吡嗪化合物会发出荧光，使用一个或多个传感器来检测。患者体内荧光减少的速率被用来计算患者的肾小球滤过率。
• COMPOSITIONS AND SYSTEMS FOR RENAL FUNCTION DETERMINATION
  申请人：MediBeacon Inc.

  公开号：US20190125901A1

  公开（公告）日：2019-05-02

  The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The system includes a computing device, a power supply, one or more sensors, and at least one tracer agent that fluoresces when exposed to electromagnetic radiation. The electromagnetic radiation is detected using the sensors, and the rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.

  本公开涉及确定肾小球滤过率或评估需要的患者的肾功能的系统和方法。该系统包括计算设备、电源、一个或多个传感器，以及至少一种示踪剂，当暴露于电磁辐射时发出荧光。传感器检测电磁辐射，患者体内荧光减弱的速率用于计算患者的肾小球滤过率。
• Pyrazine Derivatives and Uses Thereof in Renal Monitoring
  申请人：Rajagopalan Raghavan

  公开号：US20120100078A1

  公开（公告）日：2012-04-26

  The present invention relates to pyrazine derivatives such as those represented by Formulas I and II below. X 1 to X 4 of the compounds of Formulas I and II may be characterized as electron withdrawing groups. In contrast, Y 1 to Y 4 of the compounds of Formulas I and II may be characterized as electron donating groups. Pyrazine derivatives of the present invention may be utilized in assessing renal function. In particular, an effective amount of a pyrazine derivative of the invention may be administered into a body of a patient. The pyrazine derivative that is in the body may be exposed to visible and/or infrared light to cause spectral energy to emanate from the pyrazine derivative. This emanating spectral energy may be detected and utilized to determine renal function of the patient.

  本发明涉及吡嗪衍生物，如下式I和II所示。化合物的X1到X4可以被表征为电子吸引基团。相反，化合物的Y1到Y4可以被表征为电子供给基团。本发明的吡嗪衍生物可用于评估肾功能。特别地，可以将本发明的吡嗪衍生物的有效量注入患者体内。体内的吡嗪衍生物可以暴露于可见光和/或红外光以使其发出光谱能量。可以检测和利用这种发出的光谱能量来确定患者的肾功能。
• PYRAZINE DERIVATIVES WITH EXTENDED CONJUGATION AND METHODS OF USING THE SAME IN OPTICAL APPLICATIONS
  申请人：MediBeacon Inc.

  公开号：US20160090376A1

  公开（公告）日：2016-03-31

  The present invention relates to pyrazine derivatives capable of absorbing and emanating spectral energy in the visible and/or near infrared spectrum. Pyrazine derivatives of the invention may be administered to a patient in the form of a pharmaceutically acceptable composition and utilized in medical (e.g., diagnostic imaging) procedures.

  本发明涉及能吸收和辐射可见光和/或近红外光谱能量的吡嗪衍生物。本发明的吡嗪衍生物可以以药学上可接受的组合物形式被施用于患者，并用于医疗（例如，诊断成像）程序。